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AbsTrACT
background Most cases of pancreatic ductal 
adenocarcinoma (PDAC) are asymptomatic in early 
stages, and the disease is typically diagnosed in 
advanced phases, resulting in very high mortality. Tools 
to identify individuals at high risk of developing PDAC 
would be useful to improve chances of early detection.
Objective We generated a polygenic risk score (PRS) 
for PDAC risk prediction, combining the effect of known 
risk SNPs, and carried out an exploratory analysis of a 
multifactorial score.
Methods We tested the associations of the individual 
known risk SNPs on up to 2851 PDAC cases and 4810 
controls of European origin from the PANcreatic Disease 
ReseArch (PANDoRA) consortium. Thirty risk SNPs were 
included in a PRS, which was computed on the subset of 
subjects that had 100% call rate, consisting of 839 cases 
and 2040 controls in PANDoRA and 6420 cases and 
4889 controls from the previously published Pancreatic 
Cancer Cohort Consortium I–III and Pancreatic Cancer 
Case- Control Consortium genome- wide association 
studies. Additional exploratory multifactorial scores were 
constructed by complementing the genetic score with 
smoking and diabetes.
results The scores were associated with increased 
PDAC risk and reached high statistical significance 
(OR=2.70, 95% CI 1.99 to 3.68, p=2.54×10−10 highest 
vs lowest quintile of the weighted PRS, and OR=14.37, 
95% CI 5.57 to 37.09, p=3.64×10−8, highest vs lowest 
quintile of the weighted multifactorial score).
Conclusion We found a highly significant association 
between a PRS and PDAC risk, which explains more than 
individual SNPs and is a step forward in the direction 
of the construction of a tool for risk stratification in the 
population.
InTrOduCTIOn
Pancreatic ductal adenocarcinoma (PDAC) is 
the most common form of pancreatic cancer and 
represents about 85% of total cases.1 Due to the 
lack of early symptoms for most patients,2 the lack 
of reliable biomarkers and the difficulty in imaging 
its initial development,3 PDAC is typically detected 
in advanced stages,1 when there is a shortage of 
effective therapies. Surgical removal is considered 
the most effective treatment for localised disease.3
Pancreatic cancer shows a multifactorial aeti-
ology4 and the main epidemiological risk factors 
are tobacco smoking, heavy alcohol consump-
tion, type 2 diabetes mellitus, obesity and chronic 
pancreatitis.5 Family history of pancreatic cancer is 
another risk factor, with about 5%–10% of patients 
reporting affected first- degree relatives, suggesting 
a contribution of inherited genetic variation in risk.6 
As for other complex diseases, PDAC is affected 
both by rare highly penetrant mutations associ-
ated with high risk and common low- penetrance 
variants. Both genome- wide association studies 
(GWAS) and candidate gene studies have identified 
several SNPs associated with the risk of developing 
PDAC.7–17 Several SNPs with a genome- wide level 
of statistical significance (p<5×10−8) have been 
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Table 1 Description of the PANDoRA study population
Country Cases Controls Total
Czech Republic 386 450 836
Germany 1375 1791 3166
Greece 239 192 431
Hungary 260 353 613
Italy 968 1681 2649
Lithuania 56 185 241
The Netherlands 117 164 281
Poland 107 333 440
UK 111 311 422
Total 3619 5460 9079
Sex (%)
  Male 56.6 53.1 54.5
  Female 43.4 46.9 45.5
Median age 64.3 56.0 59.6
PANDoRA, PANcreatic Disease ReseArch.
identified and many others are considered potentially interesting 
since they are very close to this threshold.
Moreover, many studies showed a connection between blood 
groups and the risk of several malignancies including pancre-
atic cancer, in particular increased risk for non- O blood group 
subjects.18–22
A viable approach to reduce PDAC mortality would be 
to implement early detection. The overall incidence of the 
disease is relatively low, thus screening is not suggested for the 
general population. It would therefore be useful to have tools 
to stratify the general population and to identify a subgroup at 
higher risk among whom a regular screening could bring bene-
fits. Genetic variants can be useful for such risk stratification. 
Common variants, taken individually, are associated with a small 
increase in risk and therefore are not applicable for risk predic-
tion. However, the combination of different SNPs increases the 
cumulative effect on risk. Thus, the establishment of a multi-
genic score could lead to a better estimation of individual risk. 
This approach has already been successfully attempted for other 
cancers such as prostate,23 breast24–27 and endometrial.28 For 
pancreatic cancer a first attempt has been made, however it 
was based on a very small number of SNPs.29 The aim of this 
work was to generate a polygenic risk score (PRS) for PDAC risk 
prediction combining the effects of known risk SNPs, including 
the ABO alleles. In addition, as an exploratory analysis, we have 
included two well- known risk factors, smoking and diabetes, to 
construct a multifactorial score.
MATerIAls And MeThOds
study population
The study was conducted on 3619 patients with PDAC and 5790 
controls from nine European countries within the PANcreatic 
Disease ReseArch (PANDoRA) consortium.30 Cases were defined 
by an established diagnosis of PDAC and controls were individ-
uals of the general population without a pancreatic disease at 
recruitment, individuals that were hospitalised for non- tumour 
related causes, or blood donors. For each subject, informa-
tion on country of origin, sex and age (age at diagnosis for 
cases and age at recruitment for controls) was also available. 
In addition, for a subset of individuals, smoking (expressed as 
ever (current+former)/never smokers) and diagnosis of type 
2 diabetes (before the diagnosis of PDAC for the cases) were 
retrospectively collected. In accordance with the Declaration 
of Helsinki, written informed consent was obtained from each 
participant. Finally, we also used as a validation step genotyping 
data of 8769 PDAC cases and 7055 controls downloaded from 
the database of Genotypes and Phenotypes (dbGaP, https://www. 
ncbi. nlm. nih. gov/ gap/) (study accession numbers phs000206.
v5.p3 and phs000648.v1.p1; project reference number 12644). 
The genotyping data were obtained from previously published 
GWAS on PDAC risk: the Pancreatic Cancer Cohort Consor-
tium (PanScan I–III)7–9 and the Pancreatic Cancer Case- Control 
Consortium (PanC4).10
snP selection
In order to generate a PRS, we selected polymorphisms belonging 
to the chromosomal regions identified through previous studies 
to be associated with PDAC risk at genome- wide significance 
level (p<5×10−8, 18 SNPs) or close to that threshold (p<10−7, 
11 SNPs). In regions with multiple risk- associated SNPs, only 
SNPs not in high LD (r2<0.7) were selected. The selection was 
made based on the lowest p value with PDAC risk reported in 
the original study.
We also included SNPs necessary to infer the ABO blood 
groups from genotypes, in order to use the blood groups in the 
computation of the score. Namely, we selected rs505922, which 
discriminates O from non- O and rs8176746 that distinguishes 
between ABO A and B alleles.18 21 22 The combination of these 
two SNPs allows to reconstruct ABO blood groups. The final 
selection resulted in 30 SNPs as described in online supplemen-
tary table I.
Genotyping
Genotyping of the PANDoRA cases and controls was performed 
at German Cancer Research Center in Heidelberg, Germany, 
using TaqMan or KASP (Kompetitive Allele- Specific PCR) tech-
nology, according to the manufacturer protocol, in 384- well 
plates. In addition to the samples, no- template controls and 
duplicated samples (8%), used for quality control purposes, 
were included on each plate and genotyped under the same 
conditions. The endpoint fluorescence reading of the plates and 
the assignment of the genotype were performed using a ViiA 
7 Real- Time PCR System (Thermo Fisher Applied Biosystems, 
Waltham, MA, USA).
data filtering, statistical analysis and score computation
For PANDoRA we started from a total of 9409 subjects (3619 
cases and 5790 controls). Pearson χ2 test was used to verify that 
the genotype frequencies of the controls were in Hardy- Weinberg 
equilibrium (HWE). We eliminated one genotyping plate filled 
with 330 controls because it systematically showed a deviation 
from HWE, leaving 5460 controls. The breakdown of cases and 
controls by countries is shown in table 1.
After exclusion of subjects with missing covariates and geno-
types we used up to 2851 cases and 4810 controls to test whether 
the associations of the single risk variants replicated. The samples 
used had an average call rate of 97.6%, and a concordance rate 
between duplicated samples higher than 99%.
Considering only samples with call rate of 100%, 2879 
subjects (839 cases and 2040 controls) remained for the PRS 
in PANDoRA, consisting of the 30 variants (28 loci each identi-
fied by an individual SNP and two SNPs for the ABO locus, see 
below).
For the PanScan I–III and PanC4 data sets obtained from 
dbGaP, genotyping procedures, genotyping quality control 
checks and data collection were thoroughly reported in the 
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M/M versus M/m M/M versus m/m M versus m
Or (95% CI) P value Or (95% CI) P value Or (95% CI) P value
rs13303010 NOC2L A/G 1.34 (1.18 to 1.53) 1.3×10−5 1.95 (1.32 to 2.90) 0.001 5.7×10−8 1.42 (1.26 to 1.59) 7.8×10−9
rs351365 WNT2B G/A 0.97 (0.87 to 1.08) 0.523 0.83 (0.66 to 1.04) 0.099 0.072 0.92 (0.84 to 1.00) 0.056
rs2816938 NR5A2 T/A 1.11 (0.99 to 1.24) 0.077 1.08 (0.86 to 1.36) 0.515 0.151 1.09 (0.99 to 1.19) 0.076
rs3790844 NR5A2 T/C 0.93 (0.83 to 1.05) 0.226 0.94 (0.74 to 1.19) 0.607 0.049 0.93 (0.84 to 1.02) 0.1
rs1486134 ETAA1 T/G 1.10 (0.99 to 1.21) 0.080 1.11 (0.92 to 1.33) 0.291 0.058 1.06 (0.98 to 1.15) 0.124
rs9854771 TP63 G/A 0.88 (0.80 to 0.98) 0.019 0.81 (0.69 to 0.95) 0.010 0.003 0.91 (0.85 to 0.98) 0.016
rs2736100 CLPTM1L TERT G/T 0.97 (0.86 to 1.09) 0.614 1.21 (1.05 to 1.39) 0.008 0.012 1.09 (1.01 to 1.17) 0.018
rs2853677 CLPTM1L TERT A/G 0.78 (0.69 to 0.87) 2.47×10−5 0.77 (0.66 to 0.89) 6.3×10−4 2.5×10−4 0.85 (0.79 to 0.92) 9.1×10−5
rs2736098 CLPTM1L TERT G/A 0.90 (0.81 to 1.00) 0.050 0.85 (0.69 to 1.05) 0.123 0.004 0.85 (0.78 to 0.93) 3.6×10−4
rs35226131 CLPTM1L TERT G/A 0.81 (0.64 to 1.03) 0.085 0.41 (0.12 to 1.34) 0.139 0.012 0.89 (0.71 to 1.11) 0.296
rs401681 CLPTM1L TERT C/T 1.20 (1.07 to 1.35) 0.002 1.31 (1.14 to 1.50) 1.3×10−4 5.1×10−6 1.14 (1.07 to 1.23) 1.7×10−4
rs17688601 SUGCT C/A 0.97 (0.88 to 1.08) 0.628 0.73 (0.60 to 0.90) 0.003 0.051 0.91 (0.84 to 0.99) 0.028
rs73328514 TNS3 A/T 1.11 (0.97 to 1.26) 0.142 0.52 (0.31 to 0.89) 0.016 0.690 1.00 (0.88 to 1.13) 0.962
rs6971499 LINC- PINT A/G 0.86 (0.76 to 0.97) 0.012 0.71 (0.49 to 1.04) 0.079 0.001 0.84 (0.75 to 0.93) 0.002
rs172310 SHH C/A 1.02 (0.92 to 1.14) 0.636 0.94 (0.78 to 1.12) 0.462 0.964 1.01 (0.93 to 1.09) 0.848
rs2941471 HNF4G A/G 0.95 (0.84 to 1.07) 0.396 0.79 (0.68 to 0.92) 0.003 0.013 0.89 (0.82 to 0.96) 0.004
rs10094872 MYC A/T 1.16 (1.03 to 1.29) 0.011 1.40 (1.20 to 1.64) 2.6×10−5 2.9×10−5 1.18 (1.09 to 1.28) 2.4×10−5
rs1561927 MIR1208 T/C 0.83 (0.75 to 0.93) 0.001 0.81 (0.66 to 1.00) 0.044 3.4×10−4 0.86 (0.79 to 0.94) 0.001
rs8176746 ABO C/A 1.10 (0.96 to 1.26) 0.171 1.11 (0.68 to 1.80) 0.674 0.235 1.04 (0.92 to 1.17) 0.546
rs505922 ABO T/C 1.39 (1.24 to 1.55) 7.2×10−9 1.39 (1.20 to 1.61) 1.6×10−5 1.4×10−7 1.19 (1.10 to 1.28) 4.0×10−6
rs10991043 SMC2 T/C 1.05 (0.94 to 1.17) 0.403 1.02 (0.87 to 1.19) 0.793 0.353 1.01 (0.94 to 1.09) 0.709
rs7310409 HNF1A G/A 1.02 (0.91 to 1.14) 0.709 1.21 (1.05 to 1.40) 0.010 0.051 1.08 (1.01 to 1.16) 0.033
rs9581943 PDX1 G/A 0.95 (0.85 to 1.07) 0.431 1.17 (1.01 to 1.36) 0.043 0.052 1.07 (0.99 to 1.16) 0.092
rs9543325 13q22.1 T/C 1.18 (1.05 to 1.32) 0.005 1.43 (1.23 to 1.66) 3.2×10−6 4.1×10−6 1.18 (1.10 to 1.28) 1.3×10−5
rs8028529 15q14 T/C 1.00 (0.90 to 1.11) 0.966 1.15 (0.92 to 1.45) 0.229 0.907 1.05 (0.96 to 1.15) 0.291
rs7190458 BCAR1 C/T 1.26 (1.04 to 1.53) 0.017 1.67 (0.56 to 4.94) 0.355 0.025 1.20 (0.99 to 1.45) 0.068
rs4795218 HNF1B G/A 0.93 (0.84 to 1.04) 0.211 0.77 (0.60 to 0.98) 0.037 0.018 0.091 (0.83 to 0.99) 0.036
rs11655237 LINC00673 C/T 1.25 (1.10 to 1.41) 2.6×10−4 1.60 (1.08 to 2.39) 0.021 2.9×10−5 1.24 (1.12 to 1.39) 8.0×10−5
rs1517037 GRP C/T 0.88 (0.79 to 0.99) 0.026 0.64 (0.48 to 0.86) 0.002 0.001 0.84 (0.77 to 0.93) 3.6×10−4
rs16986825 ZNRF3 C/T 1.11 (1.00 to 1.25) 0.057 1.28 (0.97 to 1.68) 0.080 0.004 1.19 (1.08 to 1.31) 3.7×10−4
All analyses were adjusted for age, sex and geographic region of origin.
Text in bold indicates associations with p≤0.05.
m, minor allele; M, major allele; PANDoRA, PANcreatic Disease ReseArch; PDAC, pancreatic ductal adenocarcinoma.
Table 3 Association between the ABO blood groups and PDAC risk in 2361 PDAC cases and 4418 controls from PANDoRA
Cases Controls rs505922 rs8176746 blood group Or (95% CI) P value
780 1785 T/T Any OO Reference –
885 1474 T/C C/C AO 1.40 (1.24 to 1.59) 6.41×10−8
242 370 C/C C/C AA 1.53 (1.27 to 1.85) 1.09×10−5
281 481 T/C A/A BO 1.40 (1.18 to 1.67) 1.70×10−4
27 52 C/C A/A BB 1.34 (0.82 to 2.20) 0.245
146 256 T/C or C/C C/A AB 1.27 (0.82 to 2.20) 0.042
All analyses were adjusted for age, sex and geographic region of origin.
Text in bold indicates associations with p≤0.05.
PANDoRA, PANcreatic Disease ReseArch; PDAC, pancreatic ductal adenocarcinoma.
original publications.7–10 We removed individuals with gender 
mismatches, call rate <0.9, minimal or excessive heterozygosity 
(>3 SDs from the mean) or cryptic relatedness (PI_HAT >0.2). 
We performed imputation using IMPUTE431 and the 1000 
Genomes version 3 reference panel.32 The different GWAS data 
sets were each imputed separately. We discarded SNPs with a 
minor allele frequency <0.5%, completion rate <90%, evidence 
for violations of HWE (p<10−6) or low- quality imputation score 
(INFO score <0.7). The number of SNPs available in the final 
data set was 7 509 345. Principal component analysis was carried 
out including genotypes from all the populations of phase 3 of 
the 1000 Genomes Project (http://www. internationalgenome. 
org/). Individuals not clustering with the 1000 Genomes subjects 
of European descent were excluded from further analysis.
Unconditional logistic regression was used to validate the 
associations between the individual SNPs and PDAC risk. ORs, 
95% CIs and p values were calculated. The SNPs were analysed 
according to the codominant and allelic inheritance models, 
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Table 4 Associations between the genetic scores and PDAC risk
PAndorA Panscan I–III+PanC4
Controls Cases OR (95% CI) P value Controls Cases OR (95% CI) P value
Unweighted polygenic score
  First quintile 529 131 1.00 (reference) – 1220 908 1.00 (reference) –
  Second quintile vs first quintile 395 148 1.60 (1.19 to 2.17) 2.13E-03 994 980 1.31 (1.16 to 1.49) 1.92E-05
  Third quintile vs first quintile 437 185 1.94 (1.45 to 2.58) 7.07e-06 1025 1384 1.83 (1.62 to 2.06) 1.24e-21
  Fourth quintile vs first quintile 355 176 2.19 (1.63 to 2.94) 2.24e-07 870 1291 2.00 (1.77 to 2.26) 2.34e-26
  Fifth quintile vs first quintile 324 199 2.64 (1.97 to 3.54) 8.76e-11 780 1857 3.22 (2.86 to 3.64) 1.20e-71
  95th vs 5th centile 3.81 (2.15 to 6.77) 6.36e-06 5.67 (4.50 to 7.14) 9.72e-45
  95th vs 50th centile 1.76 (1.11 to 2.81) 1.67E-02 3.14 (2.72 to 3.64) 1.33e-48
Weighted polygenic score
  First quintile 410 94 1.00 (reference) – 977 675 1.00 (reference) –
  Second quintile vs first quintile 408 145 1.66 (1.20 to 2.30) 2.48E-03 980 923 1.37 (1.2 to 1.57) 1.91e-06
  Third quintile vs first quintile 408 155 1.79 (1.29 to 2.47) 4.24E-04 976 1240 1.86 (1.63 to 2.12) 5.44e-14
  Fourth quintile vs first quintile 408 204 2.28 (1.67 to 3.12) 2.50e-07 977 1402 2.09 (1.84 to 2.38) 2.32e-21
  Fifth quintile vs first quintile 406 241 2.70 (1.99 to 3.68) 2.54e-10 979 2180 3.24 (2.86 to 3.67) 1.20e-63
  95th vs 5th centile 4.56 (2.50 to 8.35) 1.19e-06 4.63 (3.63 to 5.91) 6.16e-32
  95th vs 50th centile 2.70 (1.72 to 4.22) 1.76e-05 3.15 (2.73 to 3.65) 5.87e-49
All analyses were adjusted for age, sex and geographic region of origin (PANDoRA) or the top eight principal components (PanScan I–III+PanC4).
Text in bold indicates associations with p≤0.05.
PanC4, Pancreatic Cancer Case- Control Consortium; PANDoRA, PANcreatic Disease ReseArch; PanScan, Pancreatic Cancer Cohort Consortium; PDAC, pancreatic ductal 
adenocarcinoma.
using the most common allele in controls as reference. The asso-
ciation between genotype- derived ABO blood groups and PDAC 
risk was also tested with unconditional logistic regression using 
the O group as the reference category. To validate the associ-
ations between the risk factors assessed as dichotomous vari-
ables and PDAC risk, logistic regression was used. All analyses 
were adjusted for: sex, age and country of origin (PANDoRA) 
or sex, age and the top eight principal components (PanScan 
and PanC4). Associations showing a p value less than 0.05 were 
considered significant since all these associations have been 
extensively studied and replicated elsewhere.
The genetic score was computed on the subset of subjects that 
had 100% call rate, consisting of 839 cases and 2040 controls 
in PANDoRA and 6420 cases and 4889 controls in PanScan I–III 
and PanC4, for a total of 14 188 subjects. Score quintiles were 
calculated based on their distribution in the controls. Details on 
score computation have been give elsewhere14 and in the online 
supplementary material.
We built two types of PRS, a simple unweighted score and 
a weighted score. We generated the unweighted score for each 
subject by summing the total number of risk alleles (attributing 
the value of 1 to each risk allele) and adding the value associ-
ated with the ABO groups, with a value of 0 for the OO group, 
1 for OA/OB and 2 for AB group. We generated the weighted 
score assigning to each genotype the relative OR, using the OR 
reported in the literature by GWAS on PDAC, and the same 
was done for the ABO groups. Subsequently, from the product 
of all the ORs, we obtained the weighted score of each indi-
vidual. Online supplementary table II shows an example of 
how the scores were generated. The computed score was used 
as a categorical variable, calculating the quintiles based on the 
distribution in controls. We validated the genetic scores in 6420 
PDAC cases and 4889 controls (subjects from PanScan I–III and 
PanC4 with 100% call rate) using the same statistical models 
used for the PANDoRA data set and adjusting for the top eight 
principal components to avoid confounding due to population 
stratification.
We also computed multifactorial scores (for PANDoRA only) 
complementing the genetic weighted score with variables for 
tobacco smoking and type 2 diabetes, using 101 PDAC cases 
and 250 controls. The computed scores were analysed for their 
association with PDAC risk with logistic regression, adjusting 
for sex, age and country of origin. Given the limited number 
of subjects in PANDoRA who had 100% call rate and complete 
data for the covariates, we also included in the multifactorial 
score subjects without all the genetic variants (call rate >80%, 
243 cases and 511 controls) and normalised the scores of each 
subject, in order to make them comparable, by multiplying them 
for (total number of variables)/(number of available variables) 
obtaining a ‘scaled’ score.
Receiver operating characteristic curves were constructed 
and the related areas under the curve (AUC) were calculated, to 
determine the performance of scores in discriminating individ-
uals with the disease from individuals without the disease.
resulTs
Main effects of snPs, AbO blood groups and epidemiological 
risk factors
Most of the associations between the GWAS- identified SNPs and 
ABO blood groups and PDAC risk were replicated in PANDoRA, 
using up to 2851 cases and 4810 controls (tables 2 and 3).
As expected, we observed statistically significant associations 
between smoking (with 1472 cases and 1865 controls), diabetes 
(with 1028 cases and 1906 controls) and PDAC risk (OR=2.66, 
95% CI 2.20 to 3.21, p=2×10−22 for smoking, and OR=1.46, 
95% CI 1.14 to 1.86, p=0.003 for diabetes) (online supplemen-
tary table III).
risk scores
The PRS (which includes the genetically predicted ABO blood 
groups) showed very significant associations. For the highest 
versus lowest quintile of the unweighted score we observed in 
PANDoRA an OR=2.64 (95% CI 1.97 to 3.54, p=8.76×10−11) 
P
rotected by copyright.













enet: first published as 10.1136/jm




373Galeotti AA, et al. J Med Genet 2021;58:369–377. doi:10.1136/jmedgenet-2020-106961
Genotype- phenotype correlations
Table 5 Associations between scores with genetic and non- genetic 
variables and PDAC risk in PANDoRA
Quintile Controls Cases Or (95% CI) P value
unweighted multifactorial score
First quintile 63 13 1.00 (reference) –
Second quintile vs first 
quintile
50 12 1.09 (0.45 to 2.63) 8.53E-01
Third quintile vs first 
quintile
51 27 2.55 (1.19 to 5.47) 1.60e-02
Fourth quintile vs first 
quintile
47 17 1.70 (0.75 to 3.88) 2.05E-01
Fifth quintile vs first 
quintile
39 32 3.89 (1.81 to 8.37) 5.05e-04
Weighted multifactorial score
First quintile 60 6 1.00 (reference)   
Second quintile vs first 
quintile
58 12 2.02 (0.71 to 5.75) 1.90E-01
Third quintile vs first 
quintile
51 13 2.54 (0.89 to 7.19) 8.00E-02
Fourth quintile vs first 
quintile
46 20 4.21 (1.55 to 11.4) 4.71e-03
Fifth quintile vs first 
quintile
35 50 14.37 (5.57 to 37.09) 3.64e-08
All analyses were adjusted for age, sex and geographic region of origin.
Text in bold indicates associations with p≤0.05.
PANDoRA, PANcreatic Disease ReseArch; PDAC, pancreatic ductal adenocarcinoma.
Table 6 Associations between scores scaled (call rate >80%) with 
genetic and non- genetic variables and PDAC risk in PANDoRA
Quintile Controls Cases Or (95% CI) P value
unweighted multifactorial score
First quintile 113 29 1.00 (reference) –
Second quintile vs first 
quintile
116 41 1.17 (0.65 to 2.11) 5.91E-01
Third quintile vs first 
quintile
116 62 2.17 (1.25 to 3.76) 5.96e-03
Fourth quintile vs first 
quintile
79 29 1.34 (0.71 to 2.54) 3.63E-01
Fifth quintile vs first 
quintile
87 82 3.66 (2.11 to 6.33) 3.62e-06
Weighted multifactorial score
First quintile 116 38 1.00 (reference) –
Second quintile vs first 
quintile
121 35 0.83 (0.46 to 1.50) 5.43E-01
Third quintile vs first 
quintile
98 48 1.75 (0.99 to 3.10) 5.40E-02
Fourth quintile vs first 
quintile
100 35 1.10 (0.61 to 2.00) 7.50E-01
Fifth quintile vs first 
quintile
76 87 6.01 (3.48 to 10.39) 1.28e-10
Scaled scores obtained by multiplying the score for (total number of variables)/
(number of available variables), in subjects with call rate >80%. All analyses were 
adjusted for age, sex and geographic region of origin.
Text in bold indicates associations with p≤0.05.
PANDoRA, PANcreatic Disease ReseArch; PDAC, pancreatic ductal adenocarcinoma.
and for the highest versus lowest quintile of the weighted score, 
OR=2.70 (95% CI 1.99 to 3.68, p=2.54×10−10), using 839 
cases and 2040 controls. The results are shown in table 4. The 
validation analysis performed in the PanScan and PanC4 data sets, 
using 6420 cases and 4889 controls, showed similar results. For 
the unweighted score, we observed an OR=3.22 (95% CI 2.86 to 
3.64, p=1.20×10−71) for the highest versus lowest quintile and 
OR=3.24 (95% CI 2.86 to 3.67, p=1.20×10−63) for the weighted 
score comparing the highest versus lowest quintile. When we 
restricted the analyses to the extreme tails of the distribution, we 
observed substantially larger risks, with good agreement between 
PANDoRA and the PanScan+PanC4 data set. Namely, when we 
compared the top versus the bottom 5% of the distributions. We 
observed OR=4.56 (95% CI 2.50 to 8.35. p=1.19×10−6) in 
PANDoRA and OR=4.63 (95% CI 3.63 to 5.91, p=6.16×10−32) 
in PanScan+PanC4. The results are shown in table 4.
The exploratory analysis of different multifactorial risk 
scores, using 101 PDAC cases and 250 controls, showed signifi-
cant associations as well. The results are summarised in table 5. 
The weighted score complemented with smoking and diabetes 
showed OR=14.37 (95% CI 5.57 to 37.09, p=3.64×10−8) for 
the highest versus lowest quintile. Similar statistically significant 
results were observed with the scaled score (OR=6.01, 95% CI 
3.48 to 10.39, p=1.28×10−10), which includes a larger number 
of individuals (243 cases and 511 controls). The results of the 
scaled score are reported in table 6.
evaluation of prediction performance results
The AUC value for the unweighted PRS is 0.59 (95% CI 0.57 
to 0.61) in PANDoRA and 0.61 (95% CI 0.60 to 0.63) in the 
PanScan I–III and PanC4 combined data set. The highest AUC 
value for the multifactorial scores is 0.63 (95% CI 0.59 to 0.67).
dIsCussIOn
A promising way to decrease PDAC mortality is to improve early 
detection, which can be achieved by identifying subjects at high 
risk of developing the disease. The International Cancer of the 
Pancreas Screening consortium recommends regular screening 
for subjects with at least a fivefold increased risk.33 This level 
of risk determination can be obtained by integrating genetic and 
epidemiological risk factors. In recent years a number of SNPs 
convincingly associated with PDAC risk have been reported.7–13 
They generally show a small effect on risk (OR <1.5), therefore 
individually are not very useful in risk prediction. Yet, combining 
them in a PRS may lead to a significant improvement in risk 
prediction,34 35 as already demonstrated for other diseases.36–38
The PRS reached high statistical significance both when 
unweighted and weighted, with similar ORs in PANDoRA and 
in the combined PanScan I–III+PanC4 data set, with an approx-
imately threefold increase in risk for the 20% of subjects with 
the highest score values if compared with the subjects with the 
20% lowest. The level of risk becomes more pronounced when 
looking only at the extremes of the distribution, with approx-
imately fivefold differences in risk between the top and the 
bottom 5%. This level of risk is in the same order of magnitude as 
reported for rare, highly penetrant mutations in familial pancre-
atic cancer syndromes (eg, for mutations in BRCA1, BRCA2 or 
ATM).4 The substantial concordance between PANDoRA and the 
combined PanScan I–III+PanC4 data set, based on data of about 
7000 PDAC cases and 7000 controls, makes us confident in the 
stability of these predictions.
In spite of the clear discrimination of risk level and the strong 
statistical significance, the values of the AUC based on the SNPs 
alone (ranging from 0.59 to 0.61) are not satisfactory. However, 
theoretical predictions39 and previous studies on cancer types for 
which a much larger number of risk SNPs are known23 24 36 37 have 
shown that the addition of risk variants increases the predictive 
power of PRS, to the point of envisaging their implementation 
in screening of the general population.25 Thus, it is foreseeable 
that continued efforts for discovery of novel pancreatic cancer 
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risk SNPs will enable us in the middle/long term to build scores 
with a much larger number of genetic variants, which will lead 
to much improved risk prediction.
Furthermore, it is useful to combine the genetic score with 
non- genetic risk factors obtaining a multifactorial score. This 
has already been done for other cancers and has shown slightly 
better prediction performances.23 37 40 The idea is to build a 
score that includes all known genetic variants associated with 
risk and all known epidemiological risk factors. The exploratory 
results we observed in our data set are encouraging because they 
showed a large increase in the ORs. It should, however, be noted 
that the data of the covariates in PANDoRA are largely incom-
plete and currently this prevents us from including all known 
non- genetic risk factors in the score. Moreover, as retrospective 
data, they may be subjected to recall bias. Data available from 
dbGaP for PanScan I–III and PanC4 do not include any variable 
about known risk factors; thus we could not evaluate the multi-
factorial score in the replication data set. For these reasons, we 
need to use caution in interpreting the results, but the combina-
tion of genotypes and data on risk factors seems a suitable way 
for the construction of a score that leads to the identification of 
a subgroup of subjects with very high risk. Indeed, subjects in 
the highest quintile of the multifactorial score including both 
smoking and diabetes reached an OR=14.37, which is compa-
rable to effect of rare high- penetrance disease causing mutations.
Strengths of this study are the sample size, since it is the largest 
study of this type conducted on PDAC to date, and the number of 
polymorphisms included in the computation of the genetic score, 
since all the known loci have been included in the score, unlike 
what was previously done. In addition, another clear advantage of 
this study is the external validation of the score using PanScan and 
PanC4 data. The limitations are the possible bias deriving from 
the inclusion of subjects that come from different countries and 
the fact that in PANDoRA the information on epidemiological and 
lifestyle factors is limited. In addition, it is possible that the OR 
that we observe in the multifactorial risk score is inflated, given the 
relatively small sample size (101 cases and 250 controls) that we 
could use for running that exploratory analysis.
In conclusion, in this study, we found a highly significant 
association between a PRS and the risk of PDAC onset, which 
explains more than individual SNPs and is a step forward in 
the direction of the construction of a tool for risk stratifica-
tion. Furthermore, the exploratory analysis of a multifactorial 
score was encouraging. In perspective, the implementation of 
the score with new genetic risk variants, which are continu-
ously discovered, and with complete data on epidemiological 
risk factors can lead to the achievement of a tool for risk strat-
ification of clinical utility. Such an instrument, if perfected, 
could be conceived as a tool for risk stratification in the popu-
lation, which in turn can contribute to improved early diag-
nosis. A test with relatively low predictive power as the score 
could be used to define groups of subjects at increased risk on 
which to apply screening tools and, lastly, the expensive and 
invasive imaging on the subjects that are positive.
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